Key statistics
As of last trade Roivant Sciences Ltd (87S:FRA) traded at 10.89, -10.12% below its 52-week high of 12.11, set on Nov 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.76 |
---|---|
High | 10.89 |
Low | 10.75 |
Bid | 11.01 |
Offer | 12.10 |
Previous close | 10.58 |
Average volume | 1.48k |
---|---|
Shares outstanding | 727.95m |
Free float | 499.73m |
P/E (TTM) | 2.11 |
Market cap | 8.60bn USD |
EPS (TTM) | 5.60 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
- Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
- Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
- Roivant Provides Update on Graves’ Disease Development Program
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
- Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
More ▼